Introduction
============

Craniopharyngiomas are rare sellar malformations with a low histological grade. Between 30% and 50% of all cases are diagnosed in children and adolescents, and childhood-onset (CO-) craniopharyngioma comprises 1.2%--4% of all childhood intracranial tumors, making it the most common pituitary mass in childhood \[[@b1-apem-2017-22-3-189],[@b2-apem-2017-22-3-189]\]. Craniopharyngioma patients suffer from the visual impairment, anterior and posterior pituitary hormone deficiencies, and severe obesity after tumor resection surgery \[[@b1-apem-2017-22-3-189]\]. Craniopharyngiomas can cause metabolic syndrome as a result of central obesity, increased insulin resistance, increased blood pressure, hyperlipidemia, and growth hormone (GH) deficiency or inactivity \[[@b3-apem-2017-22-3-189]-[@b5-apem-2017-22-3-189]\].

As the prevalence of pediatric obesity increases, nonalcoholic fatty liver disease (NAFLD) is increasing in children and adolescents in many developed countries. Although the prevalence of NAFLD in children varies widely depending on the diagnostic methods used, several studies have reported prevalences of 3%--10% in general pediatric populations \[[@b6-apem-2017-22-3-189]\], and this increases to 50% in CO-craniopharyngioma patients with hypothalamic involvement \[[@b7-apem-2017-22-3-189]\]. NAFLD is defined as the excessive deposition of fat in the liver, leading to a spectrum of hepatic pathologies ranging from simple steatosis in the most benign form to nonalcoholic steatohepatitis (NASH) or cirrhosis in the absence of significant alcohol consumption \[[@b6-apem-2017-22-3-189],[@b8-apem-2017-22-3-189]\]. Traditionally, fructose ingestion, visceral obesity, insulin resistance, and metabolic syndrome are considered risk factors for NAFLD \[[@b6-apem-2017-22-3-189],[@b8-apem-2017-22-3-189]\]. Oxidative stress, lipotoxicity, adipocytokines, mitochondrial dysfunction, endoplasmic reticulum stress \[[@b6-apem-2017-22-3-189]\], and bisphenol A \[[@b9-apem-2017-22-3-189]\] have all been implicated. NAFLD may also coincide with endocrine diseases such as polycystic ovary syndrome, hypothyroidism, GH deficiency, or hypercortisolism \[[@b10-apem-2017-22-3-189],[@b11-apem-2017-22-3-189]\].

Severe hypothalamic obesity has a significant negative impact on a metabolic function including NAFLD and the quality of life in long-term survivors of CO-craniopharyngioma \[[@b12-apem-2017-22-3-189]-[@b14-apem-2017-22-3-189]\]. NAFLD proved by computed tomography (CT) occurs in about 50% of young adults with CO-craniopharyngioma and is associated with elevated liver enzymes \[[@b7-apem-2017-22-3-189]\].

It is essential to understand the characteristics of CO-craniopharyngioma patients to prevent the development of NAFLD and improve their quality of life. This study describes the clinical characteristics of NAFLD in CO-craniopharyngioma patients, such as the frequency, time interval, and predictive factors.

Materials and methods
=====================

1. Subjects
-----------

The medical records of craniopharyngioma patients cared at Seoul National University Children\'s Hospital were reviewed retrospectively. During the years reviewed, the goal of the surgery was always radical excision whenever possible. We reviewed 76 patients who had their first surgery before the age of 15 years from January 1, 2000, to February 1, 2016 ([Fig. 1](#f1-apem-2017-22-3-189){ref-type="fig"}).

In our institute, liver imaging studies are not performed routinely for craniopharyngioma patients. Out of 75 patients, 32 underwent imaging studies because of elevated liver enzymes. Ultimately, 22 patients were diagnosed with NAFLD based on the imaging studies, and we reviewed the clinical courses of these patients. This study was approved by the Institutional Review Board of Seoul National University Hospital (approval number: 1608-141-787). Written informed consent was obtained from all patients.

2. Hormone replacement
----------------------

Preoperatively, all patients were evaluated regarding the need for replacement therapy with levothyroxine, hydrocortisone, and antidiuretic hormone (ADH) \[[@b14-apem-2017-22-3-189]\]. Postoperatively, hydrocortisone was tapered to a tolerable dose under 15 mg/m^2^/day and thyroid hormone was adjusted according to the free T4 level. Patients who had diabetes insipidus were placed on ADH replacement. Pituitary function tests including GH was done within 1 year of tumor surgery. If the patient agreed to take GH, GH for stature growth (0.5--0.7 mg/m^2^/wk) or GH for metabolic effect (0.1 mg/m^2^/wk) was started approximately 1 year after the final tumor treatment whenever there was no tumor recurrence. Hypogonadotropic hypogonadism was evaluated after the age of 10 years in female or 12 years in a male. All patients had GH deficiency, hypothyroidism, adrenal insufficiency, and diabetes insipidus. Hypogonadism was observed in 21 patients and the gonadal axis was not studied in the remaining case.

3. Demographics and laboratory assessment
-----------------------------------------

Height was measured twice with a Harpenden stadiometer (Holtain, Crymych, UK) and weight was measured with a digital scale. The z-score of height (height_Z), weight (weight_Z), and body mass index (BMI_Z) were calculated using the 2007 Korean National Growth Charts \[[@b15-apem-2017-22-3-189]\]. The serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured and the normal ranges were 0--40 IU/L for both. A diagnosis of NAFLD was based on evidence of a fatty liver from liver sonography or abdominal CT. The insulin-like growth factor-I (IGF-I) level \<3rd percentile was assigned using the Korean data \[[@b16-apem-2017-22-3-189]\].

4. Statistical analysis
-----------------------

All statistical analyses were conducted with IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). All continuous variables are described as the mean±standard deviation.

Results
=======

AST or ALT elevation above 40 IU/L was observed in 51 of the 75 (68.0%) CO-craniopharyngioma patients ([Fig. 1](#f1-apem-2017-22-3-189){ref-type="fig"}). Imaging studies were performed in 32 patients with elevated liver enzymes and NAFLD was detected in 22 patients by CT (n=5) or sonography (n=17). The estimated prevalence of NAFLD in CO-craniopharyngioma was 46.8% \[51×(22/32)/75\]. NAFLD was not detected in 10 patients who underwent liver sonography. Only one patient (C11) did a liver biopsy and proved to have NASH.

1. Clinical characteristics of NAFLD patients at initial operation
------------------------------------------------------------------

Of the 22 NAFLD patients, 13 (59.1%) were male patients ([Table 1](#t1-apem-2017-22-3-189){ref-type="table"}). The mean age at the time of the initial operation was 9.1±2.9 years. The preoperative anthropometric data were known in 19 cases. For the 19 patients, the preoperative height z-score was -1.17±0.87 and 4 patients (21.1%) had a height_Z \< -2. The preoperative BMI_Z of the 19 patients was 0.87±1.22 with 3 patients (15.8%) being overweight and 7 patients (36.8%) being obese.

2. Clinical characteristics at diagnosis of NAFLD
-------------------------------------------------

The mean time interval to the diagnosis of NAFLD in the 22 patients after the initial surgery was 4.3±4.0 (range, 0--12.2) years ([Table 1](#t1-apem-2017-22-3-189){ref-type="table"}). The BMI_Z at the time of diagnosis of NAFLD was 1.37±1.01. Four patients (18.2%) were overweight and 9 patients (40.9%) were obese. For the 19 patients with initial height and weight data, BMI_Z increased above BMI_Z at operation in 13 patients (68.4%) ([Fig. 2](#f2-apem-2017-22-3-189){ref-type="fig"}). The increment in BMI_Z was 1.13 (range, 0.10--2.84). The height_Z at the time of diagnosis of NAFLD was -0.40±1.35 (range, -2.82 to 2.34) ([Fig. 3](#f3-apem-2017-22-3-189){ref-type="fig"}).

Six patients (C01--C06, 27.3%) were diagnosed with NAFLD within 1 year. One was diagnosed preoperatively and three patients were diagnosed within 1 month (4, 11, and 19 days) postoperatively. All of them were given thyroid hormone, hydrocortisone, and ADH, but not GH. After the initial operation, BMI increased rapidly in 4 patients. One patient had a height_Z increment of 0.59 within 0.8 years without GH treatment.

Seven patients (C07--C13, 31.8%) were diagnosed with NAFLD within 1 to 4.9 years after the operation. Only 1 patient (C13) received GH and all seven received thyroid hormone, hydrocortisone, and ADH. Of 6 patients (C07--C12) who did not receive GH treatment, BMI_Z increased above BMI_Z at operation in 5 patients (83.3%). The increment in BMI_Z was 1.92 (range, 0.71--2.84). Only 1 patient (C08) showed a decrease in BMI_Z, but this patient was severely obese. Of the 6 patients, 4 (66.7%) showed catch-up growth ([Fig. 3](#f3-apem-2017-22-3-189){ref-type="fig"}).

Nine patients (C14--C22, 40.9%) were diagnosed with NAFLD more than 5 years after the operation, and the average time interval was 8.4±2.5 years. All of them were given thyroid hormone, hydrocortisone, and ADH. Six patients received sex steroids and 4 of these patients received GH. Height_Z increased in seven patients (C16--C22) regardless of GH treatment. Two of the 4 patients who received GH showed a decrease in BMI_Z.

3. Liver enzyme and biochemical profiles at diagnosis of NAFLD
--------------------------------------------------------------

All 22 patients with NAFLD (100%) had an elevation of either AST or ALT over the normal range (40 IU/L) before they were diagnosed with NAFLD. ALT ≥ 60 IU/L was observed in 15 patients and AST ≥ 60 was found in 17 patients. An ALT/AST ratio \> 1 was observed in 14 patients. The lipid profile was measured in 13 patients ([Table 2](#t2-apem-2017-22-3-189){ref-type="table"}). Hypertriglyceridemia was found in 9 patients and hypo-HDL (\<40 mg/dL) was observed in 7. Homeostasis model assessment-insulin resistance level greater than the mean level of normal South Korean adolescents \[[@b17-apem-2017-22-3-189]\] was observed in 9 of 12 patients. Impaired fasting glucose was observed in 4 patients. Hyperuricemia (uric acid≥7 mg/dL) was seen in 9 patients.

4. GH treatment
---------------

Only 5 patients (C13, C18, C20--C22) were given GH at NAFLD diagnosis ([Table 1](#t1-apem-2017-22-3-189){ref-type="table"}). The reasons for not giving 17 patients GH included tumor recurrence or a risk of tumor recurrence (n=8, 47.1%) or within a year after surgery or radiation therapy (n=6, 35.3%) or other causes (body imbalance, refusal, normal growth velocity). An IGF-I level\<3rd percentile was observed in 19 patients ([Table 1](#t1-apem-2017-22-3-189){ref-type="table"}). Two adults (C20, C21) with IGF-I\>100 ng/mL had received GH treatment but developed NAFLD more than 10 years after the initial operation.

Discussion
==========

NAFLD was common in CO-craniopharyngioma and the prevalence was 46.8% in CO-craniopharyngioma and especially 68.8% in CO-craniopharyngioma with liver aminotransferase ≥40 IU/L. NAFLD may develop even within a year after craniopharyngioma surgery.

Genetics, epigenetics, environmental factors, insulin resistance, and obesity all influence fat accumulation in the liver. The fatty liver is then predisposed to oxidative stress, mitochondrial dysfunction, proinflammatory cytokine imbalances, and stellate cell activation, which lead to necro-inflammation and fibrosis \[[@b18-apem-2017-22-3-189]\]. Obesity is the main risk factor for pediatric NAFLD and insulin resistance, hyperglycemia, and dyslipidemia are also strongly associated with NAFLD.

While increasing the survival of CO-craniopharyngioma patients, hypothalamic obesity may predispose to NAFLD, metabolic syndrome, and a poor quality of life \[[@b12-apem-2017-22-3-189]-[@b14-apem-2017-22-3-189],[@b19-apem-2017-22-3-189]\]. Few studies have focused on NAFLD in craniopharyngioma \[[@b7-apem-2017-22-3-189]\]. Therefore, we reviewed the clinical characteristics of NAFLD in CO-craniopharyngioma patients.

In this study, we used ALT or AST≥40 IU/L as a cutoff for imaging studies. This level exceeds the level of normal South Korean adolescents, for whom the normal AST level (IU/L) is 21.4±6.3 in boys and 19.0±5.0 in girls and the normal ALT level (IU/L) is 15.4±6.3 in boys and 12.7±5.2 in girls \[[@b17-apem-2017-22-3-189]\]. A high serum ALT within the normal range increases the risk of all components of metabolic syndrome. In this study, 2 patients (C08, C18) with NAFLD showed ALT level of 33 and 37 IU/L but AST level 79 and 61 IU/L respectively. Generally, it is known that initial NAFLD state correlates better with elevated ALT than AST. However, ALT under 40 IU/L cannot exclude the possibility of NAFLD \[[@b20-apem-2017-22-3-189]\]. ALT or AST may be within the normal range in CO-craniopharyngioma with NAFLD \[[@b7-apem-2017-22-3-189]\].

Given the progressive nature of hypothalamic obesity, inadequate GH replacement, hypogonadism in CO-craniopharyngioma, and the invasiveness of a liver biopsy, the exact prevalence of NAFLD or especially NASH in CO-craniopharyngioma is not clear. In this study, we observed AST or ALT elevation ≥40 IU/L in approximately 68% of CO-craniopharyngioma patients. Also, CT or sonographic findings typical of NAFLD were observed in 68% of the cases that underwent imaging studies. This result is consistent with that of a recently published study that showed NAFLD occurs in about 50% of CO-craniopharyngioma patients with hypothalamic involvement more than 5 years after the craniopharyngioma diagnosis \[[@b7-apem-2017-22-3-189]\]. In the United States, liver transplants attributed to NAFLD-related liver disease increased from 1.2% in 2001 to 9.7% by 2009. The recipients were older, more likely to be female, and had a higher BMI \[[@b21-apem-2017-22-3-189]\]. While simple steatosis carries a minimal risk of cirrhosis and liver failure in adults, NAFLD appears to follow a more aggressive course in pediatric cases than in adults with NAFLD \[[@b22-apem-2017-22-3-189]-[@b25-apem-2017-22-3-189]\]. The natural course of NAFLD in patients with hypothalamic and pituitary dysfunction may be more aggressive than the course of NAFLD in the general population. Adams et al. \[[@b26-apem-2017-22-3-189]\], reported that NAFLD developed relatively quickly (average, 6.4 years) in patients with pituitary/hypothalamic dysfunction (age range, 9--78 years) and the liver disease in these patients was severe; 60% of 10 patients who underwent biopsies had cirrhosis, and 14.3% of 18 NAFLD patients were either transplanted or died during follow-up.

Craniopharyngiomas have many features that can affect the development or aggravation of NAFLD independently or synergistically. Weight gain occurs before the diagnosis, progresses rapidly during the first 6--12 months after treatment, and results in severe obesity in half of the patients \[[@b1-apem-2017-22-3-189]\]. Our study showed that NAFLD could develop very early, even at the diagnosis of craniopharyngioma, and these NAFLD patients gained more weight during this period. The obesity in these children is related to hypothalamic dysfunction, resulting in disrupted or impaired sensitivity to feeding-related signals involving leptin, insulin, and ghrelin, and reductions in the basal metabolic rate, sleep disturbance, and physical inactivity \[[@b3-apem-2017-22-3-189],[@b4-apem-2017-22-3-189],[@b27-apem-2017-22-3-189]\]. Children with craniopharyngioma and hypothalamic obesity have more features of metabolic syndrome and insulin resistance than BMI-matched controls \[[@b28-apem-2017-22-3-189],[@b29-apem-2017-22-3-189]\]. NAFLD was observed in 50% of CO-craniopharyngioma patients, who tend to have more severe insulin resistance \[[@b30-apem-2017-22-3-189]\]. The relationship between NAFLD and metabolic syndrome is bidirectional, in that NAFLD can predispose to metabolic syndrome features, which can, in turn, exacerbate NAFLD or increase the development risk in those without a pre-existing diagnosis \[[@b31-apem-2017-22-3-189]\].

In our study, dyslipidemia was observed in some NAFLD patients, but dyslipidemia or hyperuricemia are insufficient as a predictor of NAFLD. NAFLD is related to endocrine diseases such as hypogonadism, hypothyroidism, GH deficiency, and hypercortisolism \[[@b11-apem-2017-22-3-189]\]. NAFLD is more prevalent in hypopituitarism patients than in control subjects, and severe GH deficiency predisposes to a serious degree of hepatic steatosis in NAFLD \[[@b32-apem-2017-22-3-189]\]. For 17 of 22 patients (77.3%), no GH was given before diagnosing NAFLD. The effect of GH replacement is controversial. In adults with GH deficiency, GH replacement improves the serum liver enzyme levels and, to optimize this effect, it is important to avoid body weight gain \[[@b33-apem-2017-22-3-189]\]. It is not clear whether GH replacement improves the NAFLD associated with CO-craniopharyngioma. Although GH therapy induced excellent linear growth in CO-craniopharyngioma patients, it failed to ameliorate the hypothalamic obesity \[[@b14-apem-2017-22-3-189],[@b34-apem-2017-22-3-189]\]. In our study, the course of NAFLD based on ALT or AST ranged from improvement, to waxing and waning, or to persistent, regardless of GH replacement during follow-up. We think that patients who recover from NAFLD or have normal liver function have a lifetime chance of developing NAFLD because risk factors such as obesity, inactivity, sleep disturbance, and metabolic syndrome may worsen at any time. IGF-I directly modulates the expression of acute-phase reactants; decreasing C-reactive protein and fibrinogen levels and circulating IGF-I levels showed inverse correlations with the NAFLD fibrosis score and inflammatory biomarkers \[[@b35-apem-2017-22-3-189]\]. An IGF-I level\<3rd percentile was observed in 19 NAFLD patients in our study. Although the IGF-I level was low, some patients showed catch-up growth of height at the time of diagnosis with NAFLD. The normal growth despite GH deficiency may be explained by a complex series of metabolic events, including obesity-induced hyperinsulinism \[[@b1-apem-2017-22-3-189]\]. Normal growth does not guarantee that the IGF-I level is sufficient to prevent NAFLD.

Preoperative and postoperative hypothalamic damage may contribute to postoperative weight gain \[[@b14-apem-2017-22-3-189]\] and poor quality of life \[[@b1-apem-2017-22-3-189]\]. In this study, most cases had surgeries through craniotomy rather than transsphenoidal approach (TSA) because TSA was used in some patients with favorable tumor location since 2010. We did not review the degree of hypothalamic damage in this study and this is one of the limitations.

There is no proven, safe, effective treatment for NAFLD \[[@b18-apem-2017-22-3-189],[@b36-apem-2017-22-3-189]\] or hypothalamic obesity \[[@b5-apem-2017-22-3-189]\] in children. Although lifestyle modification can improve NAFLD in many children \[[@b18-apem-2017-22-3-189],[@b36-apem-2017-22-3-189]\], lifestyle intervention is useless in hypothalamic obesity \[[@b5-apem-2017-22-3-189]\]. To improve the quality of life and metabolic condition, treatment should focus on preserving the hypothalamic function and optimizing lifestyle, including adherence to medical therapy, nutrition, physical activity, sleeping, social skills, and mental wellbeing.

This retrospective study had some limitation. First, we could not routinely check the biochemical parameters (liver enzyme, lipid, glucose, and insulin), lifestyle (diet, physical activity, and daytime somnolence), total or visceral body fat, and imaging studies in all patients. Second, ultrasonography was not performed in some patients with ALT or AST elevation ≥ 40 IU/L. Third, NAFLD could be missed in some co-craniopharyngioma patients with ALT or AST\<40 IU/L in these clinical settings.

In conclusion, NAFLD is common in survivors of CO-craniopharyngioma and may develop earlier than in simple obesity. If ALT or AST is elevated above 40 IU/L, the child should undergo noninvasive examinations, including ultrasonography, serum biomarkers, and transient elastography. All patients should receive the intensive, individualized lifestyle interventions as soon as possible to decrease the risk of progressive obesity, metabolic syndrome, and NAFLD.
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![Study population. We reviewed 76 patients who had their first surgery before the age of 15 years from January 1, 2000 to February 1, 2016. Out of 75 patients, 32 underwent imaging studies because of elevated liver enzymes. Ultimately, 22 patients were diagnosed with NAFLD based on the imaging studies. The estimated prevalence of NAFLD in childhood onsetcraniopharyngioma was 46.8%. AST, aspartate aminotransferase; ALT, alanine aminotransferase; CT, computed tomography; NAFLD, nonalcoholic fatty liver disease.](apem-2017-22-3-189f1){#f1-apem-2017-22-3-189}

![Body mass index z-score (BMI_Z) change after initial operation. The red lines indicate the case who was given GH at NAFLD diagnosis. BMI_Z increased above BMI_Z at the time of the operation in 13 patients (68.4%). The mean increment in BMI_Z was 1.13 (range, 0.10--2.84). NAFLD, nonalcoholic fatty liver disease.](apem-2017-22-3-189f2){#f2-apem-2017-22-3-189}

![Height z-score (Height_Z) change after initial operation. The red lines indicate the case who was given GH at NAFLD diagnosis. The preoperative Height_Z was -1.17±0.87. NAFLD, nonalcoholic fatty liver disease.](apem-2017-22-3-189f3){#f3-apem-2017-22-3-189}

###### 

Clinical and biochemical characteristics of nonalcoholic fatty liver disease patients with childhood onset craniopharyngioma

  No.   Sex   Preoprative   At diagnosis of nonalcoholic liver disease                                                                                                                                                            
  ----- ----- ------------- -------------------------------------------- -------------- ------ ------------ ------ ------- -------------- ------ ------------------------ ------------------------------------------------------- -------------------
  C01   F     12.7          -1.39                                        22.0 (0.94)    62     TSA          0.0    -1.39   22.0 (0.94)    62     No (OP within 1 yr)      \-                                                      \-
  C02   M     14.3          -1.94                                        18.3 (-0.75)   45     Craniotomy   0.0    -1.94   18.3 (-0.75)   45     No (OP within 1 yr)      \-                                                      \-
  C03   M     10.1          -0.98                                        18.6 (0.26)    \<10   Craniotomy   0.0    -0.98   19.8 (0.63)    \<10   No (OP within 1 yr)      \-                                                      \-
  C04   M     10.9          -2.82                                        19.6 (0.37)    238    Craniotomy   0.1    -2.82   22.2 (1.08)    54     No (OP within 1 yr)      \-                                                      \-
  C05   F     11.0          -0.80                                        24.2 (1.8)     \<10   Craniotomy   0.2    -0.88   26.0 (2.11)    \<10   No (OP within 1 yr)      \-                                                      \-
  C06   M     8.7           -2.08                                        17.3 (0.1)     51     TSA          0.8    -1.49   20.5 (0.98)    51     No (recurrence)          \-                                                      \-
  C07   M     13.6          -0.42                                        19.3 (-0.23)   474    TSA          1.1    -1.27   22.2 (0.49)    82     No (RT within 1 yr)      \-                                                      \-
  C08   M     9.5           -0.75                                        26.0 (2.13)    63     Craniotomy   1.6    -0.78   26.3 (1.86)    67     No (good GV)             \-                                                      \-
  C09   F     12.5          -0.45                                        14.7 (-1.96)   \-     Craniotomy   2.2    0.26    22.8 (0.88)    73     No (recurrence)          1.25                                                    \-
  C10   F     7.4           -2.31                                        18.8 (1.27)    \-     Craniotomy   2.5    -0.11   26.6 (2.46)    \<10   No (imbalance)           0.31                                                    \-
  C11   M     8.2           -1.41                                        15.0 (-0.97)   101    Craniotomy   2.6    -0.80   23.3 (1.34)    79     No (recurrence)          \-                                                      \-
  C12   F     5.8           -1.79                                        16.3 (0.53)    \<10   Craniotomy   2.9    0.90    29.0 (3.09)    31     No (recurrence)          \-                                                      \-
  C13   M     2.8           \-                                           \-             \-     Craniotomy   3.6    -2.11   16.7 (0.43)    371    Yes                      ^[\*](#tfn1-apem-2017-22-3-189){ref-type="table-fn"}^   \-
  C14   M     8.5           \-                                           \-             \-     Craniotomy   5.3    -0.90   27.8 (1.75)    53     No (recurrence)          \-                                                      \-
  C15   M     10.0          \-                                           \-             \-     Craniotomy   5.4    -2.00   25.4 (1.2)     45     No (recurrence)          1.54                                                    \-
  C16   M     6.4           0.43                                         19.6 (1.63)    \<10   Craniotomy   6.3    1.80    26.9 (1.72)    30     No (recurrence)          1.44                                                    \-
  C17   M     7.0           -2.48                                        19.8 (1.49)    \-     Craniotomy   7.8    0.87    35.8 (2.76)    86     No (refusal)             5.37                                                    \-
  C18   F     5.8           -0.80                                        19.4 (1.92)    \-     Craniotomy   8.4    0.77    19.0 (-0.3)    52     Yes                      0.37                                                    T-E 50 mg
  C19   F     5.9           -0.40                                        18.7 (1.69)    \-     TSA          8.9    0.92    24.1 (1.22)    17     No (recurrence)          \-                                                      E-V 2 mg, MP 5 mg
  C20   F     8.0           -0.34                                        24.4 (2.54)    \-     Craniotomy   10.1   2.34    23.7 (0.94)    124    Yes (intermittent use)   3.32                                                    E-V 1 mg, MP 5 mg
  C21   M     11.0          -0.59                                        27.0 (2.02)    133    Craniotomy   11.4   0.08    39.4 (3.18)    158    Yes                      6.49                                                    E-V 2 mg, MP 5 mg
  C22   F     10.3          -0.91                                        23.5 (1.81)    \-     Craniotomy   12.2   0.63    27.9 (2.05)    24     Yes (poor compliance)    7.49                                                    T-U 1,000 mg

BMI, body mass index; IGF-I, insulin-like growth factor-I; GH, growth hormone; TSA, transsphenoidal approach; OP, operation; RT, radiation therapy; GV, growth velocity; T-E, testosterone enanthate; E-V, estradiol valerate; MP, medroxyprogesterone; T-U, testosterone undecanoate.

Duration of GH replacement is not known due to outside treatment.

###### 

Metabolic profiles of nonalcoholic fatty liver disease patients with childhood onset craniopharyngioma

  No.   AST/ALT (IU/L)   Chol/TG/LDL/HDL (mg/dL)   FBS (mg/dL)   Insulin (μIU/mL)   HOMA-IR   UA (mg/dL)
  ----- ---------------- ------------------------- ------------- ------------------ --------- ------------
  C01   124/144          177/152/118/49            85            \-                 \-        7.7
  C02   63/90            187/-/-/-                 109           9.2                2.5       3.9
  C03   371/423          294/-/-/-                 87            \-                 \-        3.1
  C04   118/187          153/73/93/47              83            8.3                1.7       3.8
  C05   95/127           172/-/-/-                 98            \-                 \-        6.5
  C06   61/56            219/264/138/33            94            \-                 \-        7.8
  C07   45/140           184/175/110/36            96            8.0                1.9       11.2
  C08   79/33            163/-/-/-                 97            \-                 \-        6.7
  C09   217/153          160/-/-/-                 87            17.7               3.8       6.6
  C10   54/48            143/368/50/20             91            \-                 \-        9.9
  C11   60/120           234/404/85/37             99            17.7               4.3       5.0
  C12   55/62            117/-/-/-                 91            \-                 \-        6.5
  C13   83/94            124/-/-/-                 102           \-                 \-        3.9
  C14   40/40            141/97/81/40              91            43.9               9.9       6.2
  C15   64/108           203/202/132/41            84            14.5               3.0       8.0
  C16   73/121           125/171/76/34             89            42.8               9.4       6.0
  C17   125/42           189/118/119/46            88            15.3               3.3       7.3
  C18   61/37            140/92/86/40              124           18.8               5.8       9.3
  C19   108/142          197/231/163/26            76            16.8               3.2       5.4
  C20   45/41            195/-/-/-                 102           \-                 \-        4.5
  C21   64/93            163/-/-/-                 90            \-                 \-        10.6
  C22   75/96            176/260/86/38             89            16.9               3.7-      7.1

AST, aspartate aminotransferase; ALT, alanine aminotransferase; Chol, cholesterol; TG, triglyceride; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostasis model assessmentinsulin resistance; UA, uric acid.
